HK Stock Market Move | DIAGENS-B(02526) Rises Over 10% Again; Diagens Announces iMed-6.0 Leading on Two Rankings and 509 Application Breakthroughs

date
09:46 17/11/2026
avatar
GMT Eight
DIAGENS-B(02526) rose more than 10% again. As of press time, it was up 2.68% at HK$107.3, with turnover of HK$42.8332 million.
DIAGENS-B(02526) rose more than 10% again. As of press time, it was up 2.68% at HK$107.3, with a turnover of HK$42.8332 million. On the news front, Diagens recently announced two major achievements: its self-developed core technology medical imaging large model iMedImage (iMed-6.0) supports 19 medical imaging modalities and has just swept both the global champion and runner-up positions in the internationally authoritative multimodal benchmark MMMU (Health and Medicine subcategory) and the Shanghai Artificial Intelligence Laboratory's MedBench evaluation; at the same time, a general CT vertical model developed based on its lightweight base model iMed-6.0 Aegis has broken the industry's existing record, supporting a single chest + abdomen CT scan to cover 509 diseases and imaging signs. It is worth noting that the internationally authoritative financial media Forbes recently published an in-depth long-form article titled "How Chinese Medical AI Is Winning Back the Market," listing Diagens as the core touchstone for the revaluation of Chinese medical AI value and conducting an in-depth comparison between it and Tempus AI, the leading medical AI company whose U.S. shares have surged 90% this year. Forbes emphasized that Diagens is building the "Microsoft Office of the medical AI world" through its zero-code platform iMedLoop.